X-group (possible homology)

223 Profilin-like

Open in classification tree →

Ligands and drugs

16,400

Member domains

5,591

with ligand contacts (≤ 4 Å)

34.1% of members

4,569

with DrugDomain annotations

27.9% of members

2,612

with a DrugBank compound

15.9% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

466

Proteins with classified ligands

Superclasses bound (of 23)

8.8

Superclasses per 20 proteins

broader than 74% of the 256 X-groups with enough proteins to compare (median 7.6)

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

Superclass	Proteins	Expected	Ratio	Significance
Organic acids and derivatives	195	71.1	2.74×	q < 0.0001
Organoheterocyclic compounds	117	70.7	1.66×	q < 0.0001
Benzenoids	48	33.6	1.43×	q = 0.03
Homogeneous non-metal compounds	132	98.9	1.33×	q = 7.3e-4
Organic nitrogen compounds	19	14.7	1.30×	q = 0.30
Phenylpropanoids and polyketides	11	9.6	1.15×	q = 0.70
Organosulfur compounds	7	9.5	0.74×	q = 0.59
Organic oxygen compounds	61	91.5	0.67×	q = 6.1e-4
Homogeneous metal compounds	103	225.5	0.46×	q < 0.0001
Lipids and lipid-like molecules	23	51.2	0.45×	q < 0.0001
Nucleosides, nucleotides, and analogues	55	127.0	0.43×	q < 0.0001
Mixed metal/non-metal compounds	3	9.7	0.31×	q = 0.04
Hydrocarbons	1	3.2	0.31×	not tested

enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

DrugBank	PDB ligand	Name	Domains
DB03247	FMN	Flavin mononucleotide	268
DB18267	HEM	Ferroheme	92
DB04066	HC4	p-Coumaric acid	85
DB08375	CEF	(2R)-2-[(1R)-1-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid	46
DB03472	MA4	Cyclohexyl-Hexyl-Beta-D-Maltoside	40
DB02145	1BO	Butyl alcohol	26
DB03530	CAZ	Acylated ceftazidime	26
DB00167	ILE	Isoleucine	23
DB03147	FAD	Flavin adenine dinucleotide	23
DB03834	TBE	(3S)-3-(dioxidosulfanyl)-N-[(1Z)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine	22
DB00142	GLU	Glutamic acid	19
DB04035	CB4	Ceftazidime BATSI	19
DB08324	OHN	N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE	15
DB04447	DTT	1,4-Dithiothreitol	14
DB00139	SIN	Succinic acid	13
DB00145	GLY	Glycine	13
DB04133	CED	Degraded Cephaloridine	13
DB08081	LAE	3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE	13
DB08551	SM2	3-{(R)-(Dihydroxyboryl)[(2-thienylacetyl)amino]methyl}benzoic acid	13
DB00355	AZR	Aztreonam	12

Most frequently bound compounds

PDB ligand	Name	Domains in contact
CL	CHLORIDE ION	581
LBV	3-[2-[(Z)-[3-(2-carboxyethyl)-5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-4-methyl-pyrrol-1-ium-2-ylidene]methyl]-5-[(Z)-[(3E)-3-ethylidene-4-methyl-5-oxidanylidene-pyrrolidin-2-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid	317
FMN	FLAVIN MONONUCLEOTIDE	316
BLA	BILIVERDINE IX ALPHA	191
NAmetal	SODIUM ION	181
HEM	PROTOPORPHYRIN IX CONTAINING FE	135
NXL	(2S,5R)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide	130
CAmetal	CALCIUM ION	103
MGmetal	MAGNESIUM ION	100
HC4	4'-HYDROXYCINNAMIC ACID	89
ZNmetal	ZINC ION	74
EL5	3-[(2Z)-2-({3-(2-carboxyethyl)-5-[(E)-(4-ethenyl-3-methyl-5-oxo-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl}methylidene)-5-{(Z)-[(3E,4S)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl}-4-methyl-2H-pyrrol-3-yl]propanoic acid	73
CYC	PHYCOCYANOBILIN	64
GLN	GLUTAMINE	59
MER	(4R,5S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-5-[(2S,3R)-3-hydroxy-1-oxobutan-2-yl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid	52
Kmetal	POTASSIUM ION	50
IM2	(5R)-5-[(1S,2R)-1-formyl-2-hydroxypropyl]-3-[(2-{[(E)-iminomethyl]amino}ethyl)sulfanyl]-4,5-dihydro-1H-pyrrole-2-carboxylic acid	45
CEF	CEFOTAXIME, C3' cleaved, open, bound form	43
O6E	3-[5-[[(3~{R},4~{R})-3-ethyl-4-methyl-5-oxidanylidene-3,4-dihydropyrrol-2-yl]methyl]-2-[[5-[(4-ethyl-3-methyl-5-oxidanylidene-pyrrol-2-yl)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1~{H}-pyrrol-2-yl]methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid	42
IOD	IODIDE ION	40